European Journal of Heart Failure最新文献

{"title":"Quality of life in heart failure. The heart of the matter. A scientific statement of the Heart Failure Association and the European Association of Preventive Cardiology of the European Society of Cardiology","authors":"Maurizio Volterrani, Geza Halasz, Stamatis Adamopoulos, Pier Giuseppe Agostoni, Javed Butler, Andrew J.S. Coats, Alan Cohen-Solal, Wolfram Doehner, Gerasimos Filippatos, Ewa Jankowska, Carolyn S.P. Lam, Ekaterini Lambrinou, Lars H. Lund, Giuseppe Rosano, Marco Metra, Stefania Paolillo, Pasquale Perrone Filardi, Amina Rakisheva, Gianluigi Savarese, Petar Seferovic, Carlo Gabriele Tocchetti, Massimo Piepoli","doi":"10.1002/ejhf.3440","DOIUrl":"https://doi.org/10.1002/ejhf.3440","url":null,"abstract":"For most patients with chronic, progressive illnesses, maintaining good quality of life (QoL), with preserved functional capacity, is just as crucial as prolonging survival. Patients with heart failure (HF) experience much worse QoL and effort intolerance than both the general population and people with other chronic conditions, since they present a range of physical and psychological symptoms, including shortness of breath, chest discomfort, fatigue, fluid congestion, trouble with sleeping, and depression. These symptoms reduce patients' capacity for daily social and physical activity. Usual endpoints of large-scale trials in chronic HF have mostly been defined to evaluate treatments regarding hospitalizations and mortality, but more recently, patients' priorities and needs expressed with QoL are gaining more awareness and are being more extensively evaluated. This scientific statement aims at discussing the importance of QoL in HF, summarizing the most largely adopted questionnaires in HF care, and providing an overview on their application in trials and the potential for their transition to clinical practice. Finally, by discussing the reasons limiting their application in daily clinical routine and the strategies that may promote their implementation, this statement aims at fostering the systematic integration of the patient's standpoint in HF care.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"87 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of kidney disease progression in heart failure prognosis: Bridging the evidence gap for optimal management","authors":"Riccardo M. Inciardi, Daniel Steven, Gianluigi Savarese","doi":"10.1002/ejhf.3643","DOIUrl":"https://doi.org/10.1002/ejhf.3643","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"54 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart","authors":"Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López-Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss-Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout","doi":"10.1002/ejhf.3636","DOIUrl":"https://doi.org/10.1002/ejhf.3636","url":null,"abstract":"New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from <i>in vitro</i> two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"92 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myocardial ketone body oxidation contributes to empagliflozin-induced improvements in cardiac contractility in murine heart failure","authors":"Suzanne Nathalie Voorrips, Constantin Laurent Palm, Huitzilihuitl Saucedo-Orozco, Belend Mahmoud, Elisabeth Marloes Schouten, Anna M. Feringa, Pablo I. Sanchez-Aguilera, Kirsten T. Nijholt, Salva R. Yurista, Peter van der Meer, Herman H.W. Silljé, B. Daan Westenbrink","doi":"10.1002/ejhf.3633","DOIUrl":"https://doi.org/10.1002/ejhf.3633","url":null,"abstract":"Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiac performance and clinical outcomes in patients with heart failure, yet mechanisms underlying these beneficial effects remain incompletely understood. We sought to determine whether SGLT2i-induced improvements in cardiac function are dependent on increased cardiac oxidation of ketone bodies.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"68 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143600014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic decision making in tricuspid regurgitation: Many risk scores for transcatheter repair with no specific answer.","authors":"Sebastian Ewen, Viktoria Schwarz, Christian Besler","doi":"10.1002/ejhf.3640","DOIUrl":"https://doi.org/10.1002/ejhf.3640","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of clonal haematopoiesis with heart failure incidence and outcomes: A systematic review and meta-analysis.","authors":"Paschalis Karakasis, Eleftheria Lefkou, Konstantinos Pamporis, Dimitrios Farmakis, Dimitrios Patoulias, Antonios P Antoniadis, Stephane Heymans, Gerasimos Filippatos, Nikolaos Fragakis","doi":"10.1002/ejhf.3637","DOIUrl":"https://doi.org/10.1002/ejhf.3637","url":null,"abstract":"<p><strong>Aims: </strong>Clonal haematopoiesis (CH) is recognized as a significant risk factor for various non-haematologic conditions, including cardiovascular diseases. However, recent studies examining its relationship with heart failure (HF) have reported conflicting findings. To address these inconsistencies, the present meta-analysis aimed to evaluate the association of CH with the incidence and clinical outcomes of HF.</p><p><strong>Methods and results: </strong>MEDLINE, Cochrane Library and Scopus were searched until 12 December 2024. Triple-independent study selection, data extraction and quality assessment were performed. Evidence was pooled using three-level mixed-effects meta-analyses. Participants (n = 57 755) with CH had significantly greater risk of new-onset HF compared to the non-CH group (hazard ratio [HR] 1.23, 95% confidence interval [CI] 1.12-1.35, p < 0.0001; I² = 0%), irrespective of a prior history of coronary artery disease. CH was also correlated with a higher risk of the composite outcome of all-cause mortality and hospitalization for HF (HHF) compared to the non-CH group in patients with established HF (HR 1.84, 95% CI 1.25-2.70, p = 0.002; I² = 0%). Specifically, CH was associated with a 95% higher risk of all-cause mortality (HR 1.95, 95% CI 1.54-2.47, p < 0.0001; I² = 0%), with a 3% increase in risk for every 1% increase in variant allele fraction. Participants with concomitant HF and CH had a 56% higher risk of HHF compared to non-CH HF patients (HR 1.56, 95% CI 1.05-2.33, p = 0.029; I² = 19%).</p><p><strong>Conclusion: </strong>Clonal haematopoiesis is associated with an increased risk of incident HF and worse prognosis in individuals affected by HF. These findings highlight the potential of CH to contribute to a deeper understanding of HF, improve risk stratification, and support more personalized approaches to its management.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and tolerability of sacubitril/valsartan in chronic heart failure and reduced ejection fraction: Results from the open-label extension of the PARADIGM-HF study","authors":"Michele Senni, Pratap Paruchuru, Victor Shi, Michael Böhm","doi":"10.1002/ejhf.3634","DOIUrl":"https://doi.org/10.1002/ejhf.3634","url":null,"abstract":"&lt;p&gt;Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), is recommended by the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guideline for heart failure (HF) in patients with HF with reduced ejection faction, New York Heart Association class II−III, and by the 2021 European Society of Cardiology (ESC) guidelines to replace angiotensin-converting enzyme inhibitors (ACEIs) for reducing HF hospitalizations and death risk.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; These recommendations stem from the PARADIGM-HF trial, which showed sacubitril/valsartan's superiority over enalapril in reducing cardiovascular death or HF hospitalization by 20%, although long-term safety data beyond 27 months were not available.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;\u0000&lt;p&gt;Despite guideline recommendations, clinical practice highlights a low adoption of recommended doses of HF therapies. In CHAMP-HF, most patients received ACEIs/angiotensin receptor blockers (ARB)/ARNI, beta-blockers, and mineralocorticoid receptor antagonists; however, only 13% of patients were prescribed ARNI, with 14% at target dose.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Similarly, the ESC-HF Registry data indicate that only 30% of patients received recommended doses, often limited by adverse event (AE) concerns.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; Patients in PARADIGM-HF largely represent the real-world HF population.&lt;span&gt;&lt;sup&gt;4, 5, 7&lt;/sup&gt;&lt;/span&gt; Safety assessment of PARADIGM-HF trial over 12 months showed that sacubitril/valsartan reduced blood pressure, while enalapril increased renal impairment, hyperkalaemia, and cough incidents. The PARADIGM-HF open-label extension (OLE; NCT02226120), a single-arm follow-up study, continued safety and tolerability evaluations of sacubitril/valsartan post-trial until clinical approval (from October 2014 to December 2017) at 397 centres across 60 countries. The study enrolled patients who completed the double-blind phase of the PARADIGM-HF trial. After an initial treatment with 49/51 mg sacubitril/valsartan twice daily (BID), the dose was planned to be up-titrated to 97/103 mg, with dose adjustments based on tolerance (online supplementary &lt;i&gt;Figure&lt;/i&gt; &lt;i&gt;S1&lt;/i&gt;). Safety was assessed every 6 months. The primary outcome of the study was to evaluate the long-term (30 months) safety and tolerability of sacubitril/valsartan, based on the incidence of AEs, serious AEs, AEs leading to dose adjustments, and temporary or permanent discontinuations.&lt;/p&gt;\u0000&lt;p&gt;Adverse events were summarized by the number and percentage of patients, the severity, and its relationship to treatment. Statistical analysis was performed on the safety set, and Kaplan–Meier survival analysis was used to estimate the probability of death by study group.&lt;/p&gt;\u0000&lt;p&gt;Of the 8399 patients enrolled in PARADIGM-HF, 2060 patients were enrolled in the OLE study. Patients were considered eligible if they were enrolled and treated with double-blind study medication in PARADIGM-HF. Patients ","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"53 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute lower-limb heating improves exercise performance in individuals with heart failure with reduced ejection fraction","authors":"Fergus K. O'Connor, Surendran Sabapathy, Pramod Sharma, Llion Roberts, James R. Walsh, Aaron J.E. Bach, Alon G.M. Hopman, Menaka Louis, Bryce N. Balmain, Norman R. Morris","doi":"10.1002/ejhf.3638","DOIUrl":"https://doi.org/10.1002/ejhf.3638","url":null,"abstract":"<h2> Introduction</h2>\u0000<p>Exercise-based cardiac rehabilitation in individuals with heart failure with reduced ejection fraction (HFrEF) elicits clinically meaningful improvements in exercise capacity and quality of life while reducing hospital readmissions.<span>¹</span> Training dose is an important determinant of the response to cardiac rehabilitation, where both the volume and intensity of exercise performed are critical to the magnitude of adaptation.<span>²</span> Achieving more work (intensity, or duration) within a given session likely leads to greater adaptive responses and may improve clinical outcomes following exercise-based rehabilitation.<span>³</span> Ergogenic aids that facilitate an ability to perform more work during each rehabilitation session may therefore be of clinical importance. An acute bout of passive heating increases core, skin and tissue temperatures, augmenting blood flow and shear stress and subsequent oxygen delivery.<span>⁴</span> Therefore, we aimed to assess whether acute lower-limb heating increases femoral artery blood flow and lower-limb tissue oxygenation, that translates to increased post-heating exercise performance in individuals with HFrEF.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"2 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"If a patient does not require treatment with loop diuretics, do they really have heart failure?","authors":"John G.F. Cleland, Jocelyn Friday, Antonio Iaconelli, Narinder Kaur, Pierpaolo Pellicori","doi":"10.1002/ejhf.3628","DOIUrl":"https://doi.org/10.1002/ejhf.3628","url":null,"abstract":"Click on the article title to read more.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"52 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143545927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney status and events preceding death in heart failure: A real-world nationwide study.","authors":"Deewa Zahir Anjum, Caroline Hartwell Garred, Nicholas Carlson, Emil Fosbol, Mariam Elmegaard, Pardeep S Jhund, John J V McMurray, Mark C Petrie, Lars Kober, Morten Schou","doi":"10.1002/ejhf.3631","DOIUrl":"https://doi.org/10.1002/ejhf.3631","url":null,"abstract":"<p><strong>Aims: </strong>Chronic kidney disease is a frequent comorbidity in heart failure (HF) patients, affecting prognosis and mortality. This study investigates the relationship between kidney function and adverse kidney events preceding death in HF patients.</p><p><strong>Methods and results: </strong>We analysed registry data of HF patients who died between 2014 and 2021, with at least 1 year of HF diagnosis. Adverse kidney events, including acute kidney injury (AKI) and end-stage kidney disease (ESKD), were assessed. Patients were grouped by estimated glomerular filtration rate (eGFR) 1 year before death: eGFR ≥60, eGFR 30-59, and eGFR<30 ml/min/1.73 m². Among 36 435 HF patients who died, 37% had eGFR ≥60 ml/min/1.73 m², 46% had eGFR 30-59 ml/min/1.73 m², and 17% had eGFR <30 ml/min/1.73 m² 1 year before death. Median age was 81 years, and 61.2% were men. Adverse kidney events occurred in 13.1% of patients. AKI was inversely related to kidney function, affecting 6.5% (95% confidence interval 6.1-6.9) of those with eGFR ≥60 ml/min/1.73 m², 7.0% (6.6-7.4) with eGFR 30-59 ml/min/1.73 m², and 21.9% (20.9-22.9) with eGFR <30 ml/min/1.73 m². ESKD occurred in 0.7% (0.6-0.9), 2.6% (2.4-2.8), and 35.5% (34.3-36.7) of patients in the respective eGFR categories. In the last 3 months before death, kidney function notably declined, with increased chronic kidney replacement therapy. Factors associated with higher adverse kidney events included younger age, male sex, in-hospital death, and greater frailty.</p><p><strong>Conclusions: </strong>In HF patients, AKI and ESKD are common in the last year of life, particularly in those with lower baseline eGFR, with kidney decline accelerating in the final months.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}